Facioscapulohumeral Muscular Dystrophy (FSHD) Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)
Condition: Facioscapulohumeral Muscular Dystrophy (FSHD) Interventions: Drug: Losmapimod; Drug: Placebo oral tablet Sponsor: Fulcrum Therapeutics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 31, 2022 Category: Research Source Type: clinical trials
Fulcrum Therapeutics Announces REACH, a Phase 3 Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy
CAMBRIDGE, Mass., March 03, 2022. Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced its plans to initiate REACH, a Phase 3... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 3, 2022 Category: Pharmaceuticals Source Type: clinical trials
Examination of Operative Approach in pwFSHD (Patient With Facioscapulohumeral Muscular Dystrophy)
Condition: Facio-Scapulo-Humeral Dystrophy Intervention: Sponsor: Istanbul University-Cerrahpasa Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 26, 2021 Category: Research Source Type: clinical trials
